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The National Institute of Clinical Excellence (NICE)
was established in the United Kingdom in April 1999 to
issue guidance for the National Health Service (NHS)
on the use of selective new health care interventions.
This article describes the NICE requirements for both
incidence-based cost-effectiveness analyses and preva-
lence-based estimates of the aggregate NHS impact of
the new drug. The article demonstrates how both of
these requirements can be met using Markov modeling
techniques. A Markov model for a hypothetical new
treatment for HIV infection is used as an illustration of
how to generate the estimates that are required by
NICE. The article concludes with a discussion of the
difficulties of obtaining data of sufficient quality to in-
clude in the Markov model to ensure that the submis-
sion meets all the NICE requirements and is credible to
the NICE advisory board.
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Introduction
 
The National Institute of Clinical Excellence (NICE)
was established in the United Kingdom in April
1999. NICE plans to issue guidance for selective
new treatments and products as to whether or not
they can be recommended for routine use in the
National Health Service (NHS) [1, p13]. The guid-
ance may also specify for which indications use is
recommended as well as for which patient sub-
groups. New treatments and products will be iden-
tified that are likely to have a major impact on NHS
costs or patient health. Evidence on the clinical out-
comes and the cost-effectiveness of these innova-
tions will be collected and used to determine the
NICE guidance [1, pp7–8]. The first guidance,
“Not recommended for routine use by the NHS,”
was issued in October 1999 for zanamivir, a new
treatment for influenza. A number of other guid-
ance documents have been issued including guidance
for taxanes for breast cancer and for proton pump
inhibitors for dyspepsia (http://www.nice.org.uk).
The evaluation of the costs and benefits of the
chosen treatments will be completed jointly by the
sponsor of the treatment (if there is one), patient
groups, and the NICE appraisal staff or organi-
zations commissioned by them [1, pp3,4]. The
NICE requirements for the evaluation are set out
in their discussion document (1, AnnexC, pp29–
32, http://www.doh.gov.uk). These requirements in-
clude estimates of the incremental costs and utility
(quality-adjusted life-years) gains attributable to
the treatment compared to an appropriate com-
parator therapy, taking a lifetime perspective and
using these estimates to compute an incremental
cost-utility ratio. NICE also requires estimates of
the impact of the treatment on the NHS as a whole,
which includes estimates of the impact of the new
treatment on total NHS budgets and NHS resources
such as manpower.
The NICE discussion paper gives some guide-
lines as to how the cost utility estimates should be
developed and presented [1, Annex C, pp30–32].
These guidelines stress that estimates of the impact
of the treatment on different patient subgroups
should be presented, as well as the impact on the
total population with the condition of interest.
The guidelines also request that estimates of the
timing of the costs and benefits be presented. The
impact of the treatment on drug costs, other health
care costs, and social service costs should be pre-
sented separately as well as in total. The methods
used to derive the costs and benefits should be
transparent and adhere to current standards for
these analyses.
The guidelines for the aggregate cost impact
analysis [1, Annex C, p32] require that an esti-
mate be made of the size of the population eligible
for the new treatment. Estimates should be made
of the total increase or decrease in costs to the
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NHS if the whole eligible population were to
adopt the new treatment (assuming a 100% mar-
ket penetration). A time profile of these costs and
a sensitivity analysis based on the proportion of
eligible population receiving the treatments should
also be presented.
These guidelines raise questions about whether
current methods that have been used for cost-
effectiveness analyses can provide the information
that NICE requires for making its decisions. There
are two issues here: first, whether the methods
used provide the estimates in the format required,
and second, whether the data available are suffi-
cient to produce such estimates.
Currently, cost-effectiveness analyses are produced
using an incidence-based approach [2,3] where the
incremental costs and effectiveness for a new treat-
ment are estimated for a single cohort of individ-
uals with the condition of interest. For a chronic
illness, these estimates need to span the person’s
remaining lifetime and take into account lifetime
treatment patterns. Less often, estimates are ob-
tained for the costs and effectiveness of a new treat-
ment that take a prevalence-based perspective [3–5].
In this perspective, outcomes of the disease with
current treatments are estimated for a representa-
tive prevalence population and the impacts of the
new treatment are estimated as the impact on an-
nual population (e.g., NHS) costs and health out-
comes in Year 1, Year 2, and so on after introduction
of the new treatment. The prevalence population
is dynamic over time, with new patients acquiring
the disease and others either being cured or dying
from the disease or from other causes. To provide
NICE with the full economic evaluation that it re-
quires, both incidence-based and prevalence-based
economic evaluations should be completed.
In this article, I demonstrate how to use a Markov
modeling approach to generate both incidence-based
and prevalence-based estimates of the costs and ef-
fectiveness of a hypothetical new treatment for hu-
man immunodeficiency virus (HIV). These estimates,
derived using a Markov model, would fulfill the in-
formation needs for NICE. In the discussion, the
feasibility of the data requirements for the compre-
hensive estimates required by NICE is reviewed.
 
Methods
 
Overview
 
A set of hypothetical treatment and cost assump-
tions for HIV infection is made to illustrate the use
of a Markov model to estimate outcomes that fulfill
the NICE requirements. Markov modeling is com-
monly used in economic evaluation of new therapies
for chronic illness where discrete disease stages can
be identified and estimates of the rate of progression
between these stages can be estimated from the epi-
demiology and clinical trial literature. This type of
modeling has frequently been used in cost-effective-
ness studies for new HIV treatments [6–8].
The hypothetical model used in this article is
similar to that used in Mauskopf et al. [7] and de-
fines disease states in HIV infection as ranges in
the number of CD4 cells in the circulating blood.
There are five ranges of CD4 cells used in the anal-
ysis, 
 

 
100/mm
 
3
 
, 100–200/mm
 
3
 
, 200–350/mm
 
3
 
, 350–
500/mm
 
3
 
, and 
 

 
500/mm
 
3
 
. Utility weights for each
disease state were taken from Holtgrave and Pink-
erton [9] based on their review of empirical studies.
The cycle period for the model is 1 year and transi-
tions are assumed to occur only between adjacent
states (see Fig. 1). Utility weights, annual treatment
costs for the United Kingdom (only those likely to
change with the new treatment need be included),
incidence rates of opportunistic diseases, and hospi-
tal days for each CD4 cell count range are taken
from published estimates (see Table 1), which are
described below. A discount rate of 3% is used.
 
Transition Probabilities
 
Transition probabilities between adjacent states
(probability of moving to the next most severe dis-
ease state) for patients receiving no antiretroviral
therapy (ART) were estimated using data from
Hellinger [10] who presented estimates of the aver-
age time spent in each CD4 cell range. The transi-
tion probability was computed as the reciprocal of
these times. 
 
Annual Treatment Costs
 
Annual treatment costs and community costs in
each disease state for the United Kingdom (UK) were
estimated using data from the Chancellor et al. [6]
study and inflated to 1999 GBP (Great Britain
pounds) using the UK Hospital and Community
Health Service price index. The treatment costs in-
clude the hospital inpatient and outpatient costs
for treating a patient exclusive of the costs of ART.
These include the costs of treating the opportunistic
diseases (ODs) that occur at each CD4 cell range
as well as for general disease monitoring. The costs
of treating ODs change over time and so these costs
are illustrative only. The impact of combination
therapy on the incidence of ODs is captured in the
shift to higher CD4 cell count ranges. The commu-
nity costs include the costs of social services as well
as general practitioner services.
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Annual Incidence of Opportunistic Infections
 
Estimates of the annual incidence of cytomegalov-
irus (CMV) disease at each CD4 cell level were in-
cluded in the Markov model. These estimates were
based on the incidence rates for those with CD4
cell counts of 
 

 
100 from Bacellar et al. [11] and
modified to span all CD4 cell count ranges using
data from Simpson et al. [12]. CMV incidence was
used in the model to illustrate how the model can
be used to estimate the annual number of cases of
the opportunistic diseases.
 
Annual Number of Hospital Days
 
The annual number of days in the hospital was es-
timated for each CD4 cell range using 1993 data
from Beck et al. [13] and adjusting it to match the
disease states defined in Chancellor et al. [6] using
the method shown in Table 3 in the Chancellor ar-
ticle. The impact of the new drug on hospital days
was estimated to illustrate how the Markov model
estimates the impact of the new drug on NHS re-
sources. Use of hospital inpatient care rather than
hospital outpatient care may change over time and
so these estimates are illustrative only.
 
Assumptions about Lifetime Treatment Patterns
 
NICE requires cost-effectiveness analyses for chronic
diseases to be performed for the person’s remain-
ing lifetime. They also require estimates of the bud-
get impact of the new therapy to be made for dif-
ferent time periods after the introduction of the new
drug. To produce such estimates using a Markov
model, information is required about the current
lifetime treatment patterns and health outcomes
for the chronic disease as well as how the treat-
ment patterns and outcomes will be impacted by a
new drug. In the case of the hypothetical new HIV
drug, the analysis assumes that it will be used in
combination with existing therapies and will re-
sult in an increased life expectancy. The assump-
tions are discussed in more detail below.
In the base case, lifetime treatment for HIV in-
fection is assumed to consist of sequential treat-
ments with different double or triple combination
therapies. Specifically, the patient starts with treat-
ment with a double combination therapy at 11.50
GBP per day (daily prices for zidovudine and lami-
vudine from Duncan [14]) for 1 year, and then
continues with several different regimens of triple
combination therapy for 4 years. The triple com-
bination therapies are each assumed to cost 18.75
GBP per day (daily prices for zidovudine, lamivu-
dine, and indinavir from Duncan [14]). Several dif-
ferent combinations are necessary because not all
patients respond to any given combination and,
over time, each combination loses its effectiveness
in those who initially responded. Effective treat-
ment is assumed to result in an initial increase in
CD4 cell count, moving the patient into the next
higher CD4 cell count range and followed by no
decline in CD4 cell count for the effective time pe-
riod. The total time period with effective treatment
is assumed to be 3 years in the hypothetical base
case, after which transitions to the lower CD4 cell
count ranges occur at the no-ART transition rates
despite a further 2 years of combination therapy.
With the introduction of the new drug, the total
time period on combination therapy is assumed to
increase from 5 to 6 years. The cost per day is as-
sumed to be 11.50 GBP per day with double com-
bination therapy for 1 year, 21.00 GBP per day
Figure 1 State transition diagram for Markov model (HIV
infection).
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for triple combination therapy with the new drug
for 2 years, and 18.75 GBP per day with current
triple combination therapies for 3 years. The total
time period with effective treatment with the addi-
tion of the new drug is assumed to be 4 years, af-
ter which transitions to the lower CD4 cell count
ranges occur at the no-ART rate.
 
Use of the Markov Model to Generate
NICE Estimates
 
The incidence-based economic evaluation starts the
Markov model with two cohorts of 1000 patients
who either start therapy in a mix of different CD4
cell count ranges or who all start therapy in a single
CD4 cell count range. The cohort with the new
drug is started on a double combination, followed
by a triple combination therapy including the new
drug, followed by further triple combinations as de-
scribed above. The base case cohort is started on
double combination, followed by currently avail-
able triple combinations. The patients are followed
for their remaining lifetime and incremental lifetime
costs, quality-adjusted life-years gained, and incre-
mental costs per quality-adjusted life-year gained
are computed attributable to the new drug. Both
costs and life-years are discounted at 3%.
The prevalence-based economic evaluation starts
the Markov model with a cohort of 10,680 patients,
the estimated number of patients alive with diag-
nosed HIV infection in the United Kingdom in 1994
[15], before the use of combination therapy. These
patients are distributed across the different CD4
cell count ranges in the proportion that would be
expected in the prevalent population based on dis-
ease natural history [16]. Each year a cohort of
newly diagnosed patients is added to the existing
patients. The size of the newly diagnosed cohort is
assumed to be equal to 1,258, the estimated an-
nual number of people newly diagnosed with HIV
infection in the United Kingdom [15]. Patients
only leave the diagnosed population when they
die. The Markov model is used to track the HIV
population over the next 20 years with or without
the new drug. For each year after the introduction
of the new drug, the model computes annual NHS
costs, number of persons alive with HIV infection
in the population, quality-adjusted life-years expe-
rienced by the diagnosed population, annual cases
of CMV (as one example of an opportunistic in-
fection), and annual number of hospital days for
the diagnosed population. The outcomes estimates
presented in this article for Years 1, 3, and 6, are
not discounted to Year 0, but discounted estimates
could easily be computed using the Markov model.
 
Results
 
The results of the incidence-based analysis are shown
in Table 2. The lifetime costs, quality-adjusted life-
years, and the incremental cost per quality-adjusted
life-year gained are estimated for the prevalent pop-
ulation (an initial cohort distributed across all
“CD4 ranges”) assuming that the new drug is
started in the first year for all patients no matter
what their current CD4 cell count. The same esti-
mates are also presented for different population
subgroups, assuming that ART is started at differ-
ent CD4 cell ranges. In addition, the lifetime anti-
retroviral drug costs, hospital inpatient and outpa-
tient care costs, and community services costs are
shown for the initial cohort. The incremental cost
per quality-adjusted life-year gained is 17,541 GBP
for the hypothetical new drug for the initial cohort.
In a footnote to Table 2, the lifetime costs and qual-
ity-adjusted life-years for the initial cohort without
ART are shown for reference.
 
Table 1
 
Input assumptions for the HIV Markov model
 
CD4 cell count range
Input data
 

 
500 350–500 200–349 100–199
 

 
100
Average time in disease state (no ART) (years)* 2 1.8 1.8 1.5 1.3
(after diagnosis)
Transition probability to next worse disease state (no ART)
 
†
 
0.5 0.5556 0.5556 0.6667 0.7692
Annual hospital inpatient and outpatient costs (no ART)
 
‡
 
 (GBP) 1,834 1,834 1,834 1,912 7,490
Annual community services costs (no ART)
 
‡
 
 (GBP) 1,137 1,137 1,137 1,378 2,230
Utility weight
 
§
 
No ART 0.91 0.76 0.76 0.65 0.62
Combination therapy 0.82 0.76 0.76 0.65 0.62
Annual CMV incidence
 

 
0.0024 0.0024 0.0024 0.0750 0.2550
Annual hospital days
 
¶
 
1.13 1.13 1.13 2.87 29.9
 
*Reference [10]. 
 
†
 
Transition probability is equal to (1/time in state). 
 
‡
 
Reference [6] (1995 GBP inflated to 1999 GBP using the hospital and community health ser-
vices price index). 
 
§
 
Reference [9]. 
 

 
References [11,12]. 
 
¶
 
References [6,13].
ART, antiretroviral therapy; CMV, cytomegalovirus; GBP, Great Britain pounds.
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The results of the prevalence-based analysis are
shown in Table 3 for Years 1, 3, and 6 after the
introduction of the new drug. The annual hospital
(inpatient and outpatient) costs for the population
with diagnosed HIV infection are shown with and
without the new drug. The difference is small until
Year 6, when the effect of the prolonged life ex-
pectancy with the new drug impacts the costs. In
addition, estimates are shown, for each year, of
the number of people with diagnosed HIV infec-
tion, the quality-adjusted life-years experienced in
the year by those with diagnosed HIV infection,
the number of CMV cases, and the number of hos-
pital days with and without the new drug. With
the additional treatment regimen, the total num-
ber of people alive in any year increases over time
after Year 5. CMV cases and hospital days are
also lower in Year 6 with the new treatment com-
pared to the current treatment. In a footnote to
Table 3, the annual costs and other outcomes for
the prevalent population without ART are shown
for reference.
 
Discussion
 
The Markov model estimates for a hypothetical
new drug for HIV infection show that a new drug
that increases time on combination therapy and
life expectancy has an incremental cost-effectiveness
ratio of less than 20,000 GBP. However, the re-
sults of the cost-effectiveness analysis are sensi-
tive to the assumptions made about how long the
person continues to take ART after it is no longer
effective. The additional NHS costs with the new
therapy will be quite small in the first 5 years after
its introduction. In the sixth year the incremental
costs will be large because of the assumed extra
year on combination therapy with the new drug.
After that there will be a continuing but smaller
impact on NHS budgets because of the increased
size of the prevalent population.
The results of the analysis show that a Markov
model can easily be adjusted to compute both inci-
dence-based and prevalence-based economic eval-
uations. These two types of evaluations are neces-
sary if the NICE requirements for both cost-utility
analyses and aggregate estimates of the impact on
the NHS costs and resources are to be met. The
Markov model allows for dynamic estimates that
show how the aggregate impacts are likely to vary
over time for the first few years after the introduc-
tion of new treatments for chronic diseases.
The model assumed 100% market penetration
for the new drug in the first year for all eligible pa-
tients as required by NICE. However, not all eligi-
ble patients might be treated the first year or even
in any subsequent year. A sensitivity analysis in
which the size of the treated population is varied
 
Table 2
 
Cost utility estimates
 
Patient population
(CD4 cell count range)
Lifetime
costs
(GBP)
Quality-adjusted
life-years
remaining
Incremental
cost/QALY
(GBP)
Initial cohort* 17,541
Combination, current 5.26
Total 58,476
ART 28,539
Hospital 19,787
Community 10,150
Combination, new 5.79
Total 67,801
ART 35,803
Hospital 21,003
Community 10,995
CD4 
 

 
 100 17,892
Combination, current 50,257 3.15
Combination, new 60,083 3.69
CD4 200–349 17,030
Combination, current 58,681 5.31
Combination, new 67,952 5.85
CD4 350–500 17,830
Combination, current 62,594 6.37
Combination, new 71,751 6.88
 
*Assumed initial cohort distribution with current combination therapy is 45.2%
CD4 
 

 
 500; 21.4% CD4 350–500; 17.9% CD4 200–349; 15.5% CD4 100–199;
and 0% CD4 
 

 
 100. Lifetime costs for initial cohort with no ART is 23,378
GBP and quality-adjusted life-years remaining is 3.57.
ART, antiretroviral therapy; GBP, Great Britain pounds; QALY, quality-
adjusted life-years.
 
Table 3
 
Aggregate impact of hypothetical new drug on UK 
population diagnosed as HIV positive*
 
Annual outcomes Year 1 Year 3 Year 6
Cost (GBP)
Combination, current (
 

 
10
 
6
 
) 66.9 113.6 78.7
Combination, new (
 

 
10
 
6
 
) 66.9 123.4 151.6
Persons
Combination, current 11,938 14,454 16,868
Combination, new 11,938 14,454 17,804
Cost/person (GBP)
Combination, current 6,260 8,610 4,845
Combination, new 6,260 9,353 8,829
QALYs
Combination, current 8,439 10,250 11,814
Combination, new 8,439 10,250 12,535
CMV cases
Combination, current 149 155 562
Combination, new 149 155 502
Hospital days
Combination, current 16,200 19,000 63,759
Combination, new 16,200 19,000 60,665
 
*Assumed initial population distribution with current combination therapy is
45.2% CD4 
 

 
 500; 21.4% CD4 350–500; 17.9% CD4 200–349; 15.5% CD4
100–199; and 0% CD4 
 

 
 100. Annual outcomes for prevalent population with
no ART are total cost 29.1 million GBP, 10,680 persons, 2,725 GBP/person,
7,357 QALYs, 581 CMV cases, and 62,775 hospital days.
ART, antiretroviral therapy; CMV, cytomegalovirus; GBP, Great Britain
pounds; QALYs, quality-adjusted life-years.
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is requested by NICE. In the HIV model, to do
such a sensitivity analysis, the proportion of the
population treated could be assumed to be equal
across all CD4 cell ranges in our example, or
treatment could be targeted to different CD4 cell
ranges in the early years of availability. Thus, the
prevalence-based Markov model can readily be
adjusted to allow for staged uptake of the new
drug and would demonstrate the timing of the as-
sociated outcomes at the population level.
Data requirements are a possible problem in
several areas when performing an economic evalu-
ation using a Markov model for a chronic illness
at the time that the NICE appraisal takes place.
First, to compute cost-effectiveness ratios across
the remaining lifetime of the patient may be diffi-
cult with the available data. Information from
clinical trials is generally only available for a 6-month
to 1-year follow-up period at the time a new treat-
ment is approved for a chronic illness. Thus, there
is no clinical trial and frequently no observational
data about the duration of treatment or long-term
effectiveness of the new treatment. Extrapolations
must be made and the results of the analysis can
be very sensitive to these extrapolations. In addi-
tion, how a new drug will impact lifetime treat-
ment patterns with existing drugs for a patient
with a chronic disease is not known at the time
that a new drug is approved. This certainly is true
for HIV infection as well as for Parkinson’s disease
where newer drugs can be used in different sequences
and combinations with current drugs [17].
Second, the clinical trial data may not include
sufficient information to compute cost-effective-
ness ratios for different population subgroups as
required by NICE. For example, in the zanamivir
submission, NICE stated that there were not suf-
ficient clinical trial data on the high-risk group
(those with chronic conditions or those over 65
years of age) to estimate the cost effectiveness of
zanamivir in that subpopulation (http://www.nice.
org.uk).
Third, cost impacts of the new drug that are es-
timated using protocol-driven resource use data
from clinical trials might not reflect the resource
use and costs experienced in natural practice. In
addition, costs while first using the new treatment
might be higher than those experienced once phy-
sicians become more familiar with its attributes.
Fourth, in order to compute the aggregate im-
pacts of a new treatment, the number of patients
in the population at different levels of disease se-
verity must be known, as well as the rate at which
patients enter and leave the prevalent population
for each treatment used in the analysis. Assump-
tions must also be made about the effectiveness of
the new drug in the natural population as com-
pared to its efficacy in the clinical trial population.
Finally, data must be collected on the impact of
the new treatment on treatment patterns for the
diseased population—for example, additional phy-
sician visits for influenza.
Although this article has focused on the use of a
Markov modeling approach for generating eco-
nomic estimates that fulfill the NICE requirements,
the data issues raised apply to any other type of
modeling technique used to generate the estimates.
Markov models are quite restrictive for modeling
complex diseases with complex treatment patterns
and health outcomes. For example, for HIV infec-
tion, if viral load as well as CD4 cell count are
included as markers of disease severity, then the
required number of states and estimates of tran-
sition probabilities become quite large. Also, the
requirement that transitions be independent of
history is also a problem for modeling chronic dis-
eases. Monte Carlo simulation is a good substitute
modeling technique in these cases and can be used
to generate both incidence-based and prevalence-
based estimates.
This article has shown that NICE submissions
can be prepared using standard economic evalua-
tion techniques such as Markov models, if they
are used to produce both incidence-based and
prevalence-based estimates. Such analyses can com-
pute cost-effectiveness and aggregate impacts by
population subgroups and can estimate the timing
of the aggregate impacts. The main problem likely
to be experienced in satisfying the NICE require-
ments is a lack of experimental data to give the
level of detail that is desired. Extrapolation from
the trial data is likely to be needed as well as esti-
mates from other data sources. Inevitably, some of
the estimates will have a stronger data foundation
than others.
 
I would like to thank Louise Gaffney and Anke Richter
for their help in finding data inputs for the hypothetical
model and Larry Bell and Martin Backhouse and the
anonymous referees for their review comments.
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